TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

@article{Nyquist2013TALENengineeredAG,
  title={TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.},
  author={Michael D. Nyquist and Yingming Li and Tae Hyun Hwang and Luke S Manlove and Robert L. Vessella and Kevin A. T. Silverstein and Daniel F. Voytas and Scott M Dehm},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2013},
  volume={110 43},
  pages={17492-7}
}
Androgen receptor (AR) target genes direct development and survival of the prostate epithelial lineage, including prostate cancer (PCa). Thus, endocrine therapies that inhibit the AR ligand-binding domain (LBD) are effective in treating PCa. AR transcriptional reactivation is central to resistance, as evidenced by the efficacy of AR retargeting in castration-resistant PCa (CRPC) with next-generation endocrine therapies abiraterone and enzalutamide. However, resistance to abiraterone and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Cancer statistics , 2013

  • NaishadhamD Siegel R, A Jemal
  • CA Cancer J Clin
  • 2013

Mechanisms of the androgen receptor splicing in prostate cancer cells

  • LL Liu
  • 2013
2 Excerpts

Similar Papers

Loading similar papers…